Drug intelligence / Profile preview

Coldanese Plus

Development stage: Unknown
Lead developer: Nafas Zist Pharmed
Administration: Intranasal

Overview

Coldanese Plus is an herbal nasal spray developed by Nafas Zist Pharmed for the treatment of respiratory tract infections and associated symptoms. The formulation typically combines extracts of *Pelargonium sidoides* and *Sambucus nigra* (Elderberry), which are recognized for their antiviral, antibacterial, and immunomodulatory properties. It is indicated for the management of the common cold, influenza, and coronavirus infections, as well as for relieving nasal congestion and allergic rhinitis. The drug is approved for use in Iran and is delivered via the intranasal route to provide localized therapeutic effects in the upper respiratory tract.

Brand names: Coldanese Plus
Other names: Coldanese Plus Nasal Spray

Beyond the preview

Go deeper on Coldanese Plus.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Coldanese Plus.

Explore the full profile